|
|
| How Congress Can Help Biosimilars Succeed | By Anna Rose Welch, Editorial & Community Director, Advancing RNA, Biosimilar Development | In the third, most recent installment of The Atlantic’s biosimilar policy update, Vermont Representative Peter Welch homed in on several misperceptions and hesitations within Congress which are serving as a stumbling block to government-assisted cheaper prices, as well as the timely market entry of biosimilars. |
|
|
| The Importance Of Options In Biosimilar Litigation | By Anna Rose Welch, Editorial & Community Director, Advancing RNA, Biosimilar Development | A recent discussion amongst experts from Momenta, Eli Lilly, and Foley & Lardner highlighted the diversity of opinions surrounding Amgen v. Sandoz and other legal challenges in the space. But lurking underneath discussions of statutes and standards of evidence is biosimilar makers' desires for options to address the U.S.' rigid patent landscape. |
|
|
